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ABSTRACT
Iron is proposed to contribute to the transition from endometriosis to specific 
subtypes of ovarian cancers (OVCAs). Regulation of intracellular iron occurs via a 
ferritinophagic process involving NCOA4 (Nuclear Receptor Coactivator 4), represented 
by two major isoforms (NCOA4α and NCOA4β), whose contribution to ovarian cancer 
biology remains uninvestigated. We thus generated transformed endometriotic 
cells (via HRASV12A, c-MYCT58A, and p53 inactivation) whose migratory potential was 
increased in response to conditioned media from senescent endometriotic cells. 
We identified elevated NCOA4 mRNA in transformed endometriotic cells (relative 
to non-transformed). Knockdown of NCOA4 increased ferritin heavy chain (FTH1) 
and p21 protein which was accompanied by reduced cell survival while NCOA4β 
overexpression reduced colony formation. NCOA4α and NCOA4β mRNA were elevated 
in malignant versus non-malignant gynecological cells; NCOA4α protein was increased 
in the assessed malignant cell lines as well as in a series of OVCA subtypes (relative 
to normal adjacent tissues). Further, NCOA4 protein expression was regulated in a 
proteasome- and autophagy-independent manner. Collectively, our results implicate 
NCOA4 in ovarian cancer biology in which it could be involved in the transition from 
precursors to OVCA.
www.impactjournals.com/oncotarget/                      Oncotarget, 2018, Vol. 9, (No. 4), pp: 5344-5367
INTRODUCTION
Ovarian cancer (OVCA) is one of the deadliest 
gynecological cancers in women [1]. Precursors to OVCA 
include endometriotic lesions (proposed to transition to 
clear cell/endometrioid) as well as fallopian tube fimbriae 
and/or ovarian surface epithelium (proposed to transition 
to serous) [2]. The mechanisms underlying the transition of 
these precursors, such as endometriosis, to OVCAs remain 
unclear. Evidence implicates an array of mutations and 
genomic aberrations that contribute to OVCA development 
[3]. These include the (a) c-MYC proto-oncogene, located 
at 8q24.21, which is frequently amplified in >20% of 
OVCAs [3], (b) p53 tumor suppressor, located at 17p13.1, 
which is mutated in ~95% of OVCAs [3], and (c) KRAS 
proto-oncogene, located at 12p12.1, which is amplified in 
>10% of OVCA patients [3]. In addition, the HRAS proto-
oncogene, located at 11p15.1, is frequently activated due 
to upstream alterations in signaling pathways; mutations 
in its gene have been rarely identified [4]. There are 
reports that alterations in the above described genes can 
be mediated by reactive oxygen species (ROS) [5]. It is 
suggested that ROS may be generated by high levels of 
redox-active iron (mM levels) in endometriomas [6] as 
well as in the fallopian tube [7]. Indeed, as a result of its 
ability to undergo Fenton reactions, iron is considered to 
be highly mutagenic [8, 9]. Furthermore, increased DNA 
damage is noted in fallopian tube secretory epithelial cells 
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in response to transferrin [10] and cellular treatment with 
iron leads to their increased proliferative capacity [11]. 
Nonetheless, the exact role of iron in mediating OVCA 
pathogenesis requires clarification. Iron levels need to 
be balanced appropriately within the cell; excess iron is 
frequently stored in ferritin as a storage complex (for a 
comprehensive review on iron regulation, see [12]). When 
iron is required by the cell, it may be released via the 
process of ferritinophagy, which is mediated by Nuclear 
Receptor Coactivator 4 (NCOA4) [13] leading to increased 
redox-active iron that may be utilized for regulation of 
enzymatic activities which requires formation of iron-
sulfur clusters [14]. Two well-studied NCOA4 isoforms 
(NCOA4α and NCOA4β) have been functionally assessed 
in breast and prostate cancers [15–18]. Specifically, 
NCOA4α inhibits proliferation in prostate cancer whereas 
NCOA4β increases proliferation in both prostate and 
breast cancer cells [17, 18]. Thus far, there is only limited 
data describing increased NCOA4 transcripts in ovarian 
carcinomas [19]; thus, the contribution of NCOA4 to 
the progression of OVCA has not yet been thoroughly 
investigated.
Herein, we successfully developed a transformed 
endometriotic cell line via overexpression of HRASV12A 
and c-MYCT58A with p53 inactivation. These cells were 
able to overcome cellular senescence and displayed 
altered mRNA expression of genes involved in the EMT 
and iron pathways, notably NCOA4. Knockdown of 
this nuclear receptor coactivator in normal/benign and 
malignant gynecological cells resulted in reduced cell 
survival. In malignant gynecological cells compared to 
non-malignant, we identified increased mRNA transcripts 
for two NCOA4 isoforms (NCOA4α and NCOA4β) as 
well as increased NCOA4α protein. We additionally 
identified increased NCOA4 expression in ovarian tumors 
(serous, serous papillary, and mucinous) compared to 
adjacent normal tissues via tissue microarray analyses. 
Together, our results demonstrate that NCOA4 expression 
is elevated in transformed endometriotic cells (relative 
to non-transformed endometriotic cells) as well as 
malignant OVCA cells (relative to non-malignant cells) 
and furthermore, this molecule appears to regulate survival 
of these gynecological cells.
RESULTS
Characterization of transformed endometriotic 
cells and their increased migratory response 
to conditioned media from primary senescent 
endometriotic cells
To begin to delineate the process involved in the 
transition from endometriotic precursors to ovarian 
carcinomas, long-term culturable endometriotic cells 
are necessary. However, due to a limitation in the 
availability of characterized cell lines (i.e., immortalized 
and/or transformed human endometriotic cells), this 
remains a challenge. Thus, we made attempts to generate 
endometriotic cell lines that could be maintained in culture 
long-term without reaching senescence. As described in 
the Methods, we obtained primary cells derived from 
four different human endometriotic lesions: PE-A, PE-B, 
PE-C and PE-D. We infected these pools of endometriotic 
cells with an oncogenic retrovirion cocktail (termed 
OCV) containing SV40 LTAg (which targets p53 and 
Rb), hTERT, c-MYCT58A, and HRASV12A (as outlined 
in Figure 1A) based on a similar strategy described for 
fimbrial epithelial cell transformation [20]. We were 
successful in obtaining transformants for the PE-A and 
PE-B endometriotic cells. We validated expression of 
the oncogenic markers via western blotting (Figure 
1B, Supplementary Figure 1A, and 1E). While hTERT 
protein was undetectable (data not shown), expression 
of LTAg, HRAS, and c-MYC were clearly increased in 
OCV relative to CV infected cells. Additionally, we noted 
increased expression of ID1 and pAKT with reductions in 
pMAPK, suggestive of bypassing senescence [21]. Indeed, 
results from the colony formation assay (Figure 1C and 
Supplementary Figure 1B) and β-galactosidase staining 
(Figure 1D and Supplementary Figure 1C) support that 
CV infected cells senesced in contrast to OCV infected 
cells which were proliferative, lacked senescent cells, and 
demonstrated increased DNA damage foci upon staining 
with a γH2AX antibody (Figure 1E and Supplementary 
Figure 1D). In addition, we noted that PE-A-OCV and PE-
B-OCV cells elicited in vitro tumorigenic potential (in the 
3D morphogenesis assay after 10 days of growth) (Figure 
1F and Supplementary Figure 1F). We also identified 
increased IL-6 mRNA in OCV infected PE-A and PE-B 
cells relative to controls (Figure 1G and Supplementary 
Figure 1G), which has been correlated with increased 
tumorigenicity [22]. To note, although three biological 
replicates were available for PE-B cells (both CV and 
OCV infected), statistical significance could not be 
determined for PE-A cells due to limitations in available 
numbers of CV-infected cells as a result of reaching 
senescence (one biological replicate). Collectively, these 
data indicate that we successfully obtained transformed 
endometriotic cells upon HRASV12A and c-MYCT58A 
overexpression together with p53 inactivation, which are 
characterized by increased in vitro tumorigenic potential. 
Further characterization of these transformed 
endometriotic cells (PE-A-OCV and PE-B-OCV) 
identified markedly elevated mRNA transcripts for 
EMT pathway genes (SNAIL, SLUG, TWIST, ZEB1, 
and ZEB2) (Figure 1H and Supplementary Figure 1H) 
relative to their CV infected counterparts suggesting that 
the transformed endometriotic cells may have increased 
migratory potential. However, we unexpectedly discovered 
that the OCV infected cells were less migratory (~31–39%, 
p-value = 0.005–0.0014, for PE-A-OCV and PE-B-OCV, 
respectively) (Figure 2A and Supplementary Figure 2A 
Oncotarget5346www.impactjournals.com/oncotarget
(left and right panels)) and more cuboidal compared to CV 
infected cells (Figure 2B and Supplementary Figure 2B). 
Since senescent cells are capable of inducing cellular 
migration of those nearby via secretion of factors, namely 
the senescence-associated secretory phenotype (SASP 
[23]), we collected conditioned media (COM) from 
senescent cultures of endometriotic cells (CV-infected) 
and used it as a chemoattractant to assess motility (using 
complete media (CM) as a control). As shown in Figure 
2C (left and right panels), we noted increased migratory 
capacity of transformed endometriotic cells with COM 
media (PE-A-OCV (2.4-fold, p = 0.0550) and PE-B-
Oncotarget5347www.impactjournals.com/oncotarget
Figure 1: Transformation of human primary endometriotic cells. (A) Schematic depicting the overall strategy involving 
retroviral infections (with control virus (CV) or oncogenic cocktail virus (OCV: comprised of HRASV12A, c-MYCT58A, SV40 LTAg, 
and HA-hTERT)) to generate transformed endometriotic from primary cells (PE-A, PE-B, PE-C, and PE-D; * refers to life-extended 
PE-D cells with SV40 LTAg) isolated from endometriotic lesions. Two batches of transformed endometriotic cells were successfully 
obtained using PE-A and PE-B primary cells. The first batch of retrovirally infected cells (PE-B-CV and PE-B-OCV) were utilized to: 
(B) obtain cell lysates for western blotting with the indicated antibodies (left panel). The dotted line specifies re-run samples to avoid 
the possibility of detecting overlapping bands of similar molecular weights. Densitometric analyses for pAKT and pMAPK are shown 
in the right panels; (C) perform colony formation assay and images were captured following 14 days in culture (representative images 
are shown, three independent experiments were conducted); (D) perform β-galactosidase staining and images were captured at 100× 
magnification (representative images are shown, three independent experiments were conducted); and (E) assess DNA damage via γH2AX 
immunofluorescence staining (representative images shown were captured at 63× magnification and the images of nuclei were enlarged and 
cropped using PowerPoint to focus on the DNA damage foci). The second batch of retrovirally infected cells (PE-B-CV and PE-B-OCV) 
were utilized to: (F) assess the in vitro tumorigenic potential (by 3-dimensional morphogenesis assay in Matrigel). Representative images 
(from four independent experiments) were captured at 100× (left) and 200× (right) magnification; (G) to measure IL-6 transcript levels via 
real-time PCR. Three independent experiments were performed; and (H) assess transcript levels for genes in the EMT pathway via real-time 
PCR (three independent experiments were performed).  
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OCV cells (4.1-fold p < 0.0001)) compared to CM. This 
increased migratory phenotype in response to COM 
media was not accompanied by dramatic alterations 
in EMT marker mRNA expression in the PE-A-OCV 
and PE-B-OCV cells relative to CM-treated (Figure 
2D). We next investigated whether the above observed 
phenomena were accompanied by changes in cellular 
morphology via staining with phalloidin; indeed, COM 
mediated an elongated cell morphological change in the 
transformed endometriotic cells compared to CM-treated 
cells (Figure 2E). Collectively, these data suggest that the 
senescent endometriotic cells are capable of increasing the 
migratory capacity of nearby cells. 
Transformed endometriotic cells elicit alterations 
in iron pathway markers including NCOA4
Oncogenic alterations (associated with increased 
growth potential) has been reported to lead to changes 
in intracellular iron levels as a result of changes in the 
expression of iron pathway signaling mediators such as the 
transferrin receptor (CD71), ferroportin (FPN), and ferritin 
complex amongst several others [24–27]. However, 
whether oncogenic transformation of endometriotic 
cells (as a precursor lesion for specific ovarian cancer 
subtypes) leads to changes in the expression of iron 
pathway signaling mediators including NCOA4, a novel 
intracellular regulator of intracellular iron levels [28, 29], 
has not yet been investigated. As described earlier, there 
exists two well-studied NCOA4 isoforms (NCOA4α and 
NCOA4β) with opposing functions in breast and prostate 
cancers [17, 18]. The alignment of NCOA4β (missing 
an internal 327 amino acid sequence) with a published 
NCOA4α protein sequence (accession #: Q13772) is 
presented in Supplementary Figure 3A. The role of these 
isoforms in ovarian cancer remains uninvestigated other 
than one report of increased NCOA4 mRNA levels in 
ovarian tumor specimens relative to ovarian surface 
epithelium (via in situ hybridization [19]).
In our transformed endometriotic cells, we observed 
multiple alterations in iron pathway markers including 
an increase in CD71 and DMT1 (PE-A-OCV and PE-
B-OCV) as well as FPN and ISCU (PE-B-OCV), with a 
reduction in FTH1 mRNA (PE-A-OCV and PE-B-OCV) 
(Figure 3A and Supplementary Figure 3B). To investigate 
the expression of the two NCOA4 isoforms in these cells, 
we first needed to generate custom-designed probes and 
primers to target NCOA4α (spanning the junction between 
exon 8 and exon 9) and NCOA4β (spanning the junction 
between exon 7 and exon 9 (Supplementary Figure 3C 
depicts the binding location of these probes)) for real-
time PCR. The specificity of these probes was assessed 
using RNA isolated from NCOA4α overexpressing 
T80 cells and NCOA4β overexpressing HEY cells. As 
shown in Supplementary Figure 3D, these probes could 
distinguish between these two splice variants (NCOA4α 
and NCOA4β mRNA mRNA (~8-fold and ~147-fold 
increase, respectively) relative to their corresponding 
controls. As shown in Supplementary Figure 3E and 3F, 
a corresponding ~2-fold and ~6-fold increase in NCOA4α 
(70 kDa) and NCOA4β (35 kDa) protein was noted. We 
next identified a ~2.2–2.6-fold (p = 0.0084) increase 
for NCOA4α and a ~1.3–1.6-fold increase (p = 0.0026) 
for NCOA4β in PE-A-OCV and PE-B-OCV relative to 
non-transformed cells (Figure 3B and Supplementary 
Figure 3G). These data indicate that cellular transformation 
of primary endometriotic cells leads to increases in the 
mRNA levels of both NCOA4 isoforms.
NCOA4 is localized predominantly to the 
cytoplasm and modulates cellular viability of 
T80, HEY, and PE-A-OCV cells
Since there is evidence describing the localization 
of NCOA4 isoforms in the cytosolic and nuclear 
compartments of prostate tissues (possibly to mediate 
its function as a hormone receptor coactivator [16, 30] 
[31, 32]), we next investigated the localization of this 
iron mediator in our gynecological cells. As shown in 
Figure 3C, we identified that NCOA4α was localized 
predominantly to the cytoplasmic fraction (with no 
detectable expression in the nuclear fraction) in T80, HEY, 
and PE-A-OCV cells; to note, NCOA4β protein was not 
detected in these cells (data not shown). 
To investigate the role of NCOA4 in gynecological 
cell survival and determine whether its activity is altered 
upon exposure to iron, we reduced NCOA4 levels in 
normal/benign immortalized cells (T80 and T-HESC), in 
transformed human endometriotic cells (PE-A-OCV), and 
in OVCA cell lines (HEY and TOV21G) using an siRNA 
approach. In addition, we tested the effect of NCOA4 
knockdown in the absence or presence of ferric ammonium 
citrate (FAC) as we previously tested the effects of iron 
overload conditions (using FAC) in HEY cells [33]. As 
shown in Figure 3D, NCOA4 protein was reduced upon 
knockdown by ~65% in T80, ~75% reduction in HEY, 
~55% in T-HESC, ~65% in TOV21G, and ~50% in PE-A-
OCV (we identified reduced NCOA4 mRNA using a real-
time PCR probe/primer detecting all isoforms (~74% in 
T80, ~94% in HEY, and ~71% in PE-A-OCV cells (Figure 
3F); see Supplementary Figure 3H for NCOA4 isoform 
specific probes/primers real-time PCR data)). NCOA4 
protein was not further altered by FAC (Figure 3D). The 
NCOA4 antibody also detected a ~55 kDa immunoreactive 
band that has been previously reported [34] which we 
found to be reduced upon NCOA4 knockdown; the identity 
of this band remains unclear. Upon reduction of NCOA4, 
we observed increases in FTH1 protein in all cell lines 
whereas increases in p21 (cyclin-dependent kinase inhibitor 
which is elevated under conditions of growth arrest [35]) 
were identified in T80 (~3.5-fold), HEY (~2-fold), and PE-
A-OCV cells (~2-fold). In this respect, we determined that 
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there was an association between elevated p21 (following 
NCOA4 knockdown) with inactivated p53 (in T80 and 
PE-A-OCV cells which express LTAg which binds to p53 
(results not shown and [36])) or undetectable p53 (in HEY 
cells (results not shown)) whereas T-HESC and TOV21G 
have wild type p53 levels (results not shown and [37]) 
and were not associated with changes in p21 levels with 
reduced NCOA4. Knockdown of NCOA4 reduced cellular 
viability by ~31%, 36%, and 33% in T80, HEY, and PE-A-
OCV cells, respectively (Figure 3E). 
We additionally observed increases in FTH1 (T80 
cells), CD71 (T80 and HEY cells), and FPN (T80 and PE-
A-OCV cells) mRNA levels (Figure 3F). Since NCOA4 
is a regulator of ferritinophagy, we also examined the 
transcript profile for genes involved in autophagosome or 
lysosome formation. In this regard, we identified increases 
in SQSTM1 (~1.5-fold (T80) and ~2-fold (HEY)) 
involved in autophagic flux [38] and in MCOLN1 (~1.2-
fold (T80)) involved in iron transport to lysosomes [39]. 
Since cellular viability was reduced with NCOA4 siRNA, 
Oncotarget5350www.impactjournals.com/oncotarget
Figure 2: Conditioned media from senescent primary endometriotic cells promotes migration of transformed 
endometriotic cells. The second batch of retrovirally infected cells (PE-B-CV and PE-B-OCV) were utilized to: (A) perform migration 
assay. Representative images (from four independent experiments) were captured at 100× magnification (left panel). Manual cell counts 
are presented in the right panel; and (B) assess actin filament organization using phalloidin staining. Representative images (from three 
independent experiments) are shown at 63× (top panel) and 20× (bottom panel) magnification. The second batch of retrovirally infected 
cells (PE-A-OCV and PE-B-OCV) were utilized to: (C) assess migration using either complete media (CM) or senescence-conditioned 
media (COM) as the chemoattractant. Representative images (from four independent experiments) are shown at 100× magnification (left 
panel). Manual cell counts are presented in the right panel; (D) assess transcript levels for genes in the EMT pathway via real-time PCR 
using RNA from these cells treated for 24 hours with CM or COM media (three independent experiments were performed); (E) assess actin 
filament organization via phalloidin staining in cells treated with CM or COM for 24 hours. Representative images (from three independent 
experiments) are shown at 63× (top panel) and 20× (bottom panel) magnification. 
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we next investigated the effect of NCOA4 knockdown 
on markers of tumorigenicity including those involved 
in EMT progression and identified an increase in SNAIL 
(~1.6-fold in both T80 and PE-A-OCV cells) with a 
decrease in SLUG (~28% in PE-A-OCV cells) and TWIST 
(~55% in HEY cells) transcripts which further implicate 
NCOA4 in promoting cellular survival.
Expression of NCOA4 is regulated by factors 
present within serum
Fetal bovine serum, commonly used for promoting 
cell growth and attachment, consists of multiple factors 
(such as growth factors, cytokines, hormones, and other 
lipophilic proteins) which can be removed by charcoal-
Oncotarget5352www.impactjournals.com/oncotarget
Figure 3: NCOA4 knockdown reduces cellular viability in T80, HEY, and PE-A-OCV cells. Transcript levels for (A) genes 
in the iron pathway including (B) NCOA4α and NCOA4β were assessed via real-time PCR using RNA extracted from the second batch of 
PE-B-CV and PE-B-OCV cells. Three independent experiments were performed. (C) Western analyses of cytoplasmic and nuclear fractions 
from T80, HEY, and the first batch of PE-A-OCV cells were performed using the indicated antibodies. Data shown is representative of three 
independent experiments. (D) Cell lysates from NCOA4 siRNA treated T80, HEY, TOV21G, T-HESC, and the second batch of PE-A-OCV 
(treated for 18 hours with 250 µM FAC) were analyzed by western blotting using the indicated antibodies. Data shown are representative 
of three independent experiments. (E) Cellular viability (via ATP measurements) was assessed upon NCOA4 knockdown in T80, HEY, 
and the second batch of PE-A-OCV (2nd batch) cells. Three independent experiments were performed. (F) Using RNA isolated from T80, 
HEY and the second batch of PE-A-OCV treated with NCOA4 siRNA, transcript levels for genes in the iron, EMT, lysosome/autophagy 
pathways were measured via real-time PCR. Three independent experiments were performed.
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dextran treatment [40]. To assess whether our observed 
biochemical and functional changes mediated by NCOA4 
are dependent on these above-described factors, we 
utilized media deficient in phenol red and charcoal-
dextran treated FBS (-PR) following NCOA4 knockdown. 
We completed these analyses using HEY as these cells 
showed a more robust cellular effect in response to 
NCOA4 knockdown relative to T80 and PE-A-OCV cells. 
As shown in Figure 4A, the use of –PR media increased 
LC3B-II, FTH1, and p21 basal protein expression relative 
to complete (+PR) media; FTH1 and p21 protein were 
not further altered upon NCOA4 knockdown in –PR 
media. We also noted that cell viability was reduced in 
HEY cells in –PR relative to +PR conditions, with either 
control or NCOA4 siRNA (Figure 4B). While we observed 
significant reduction of NCOA4 mRNA upon NCOA4 
knockdown under both media conditions (+PR and –PR), 
the NCOA4 mRNA (assessed with the commercially 
available Taqman probe and primers) increased by ~2-
fold (p = 0.0027) in –PR conditions suggesting that the 
presence of these serum factors could potentially inhibit 
NCOA4 transcription (Figure 4C, top left panel). Although 
CD71 mRNA increased upon NCOA4 knockdown 
(relative to control siRNA) in +PR media (~3.6-fold, 
p = 0.0046), this increase was reduced in -PR media 
(~1.4-fold, p = 0.0761). We noted a further reduction 
in TWIST mRNA in –PR media upon NCOA4 siRNA 
treatment relative to control siRNA (~65% reduction, 
p = 0.0012 compared to ~55% reduction, p = 0.0002). 
Further, SQSTM1 mRNA was not as markedly increased 
with NCOA4 siRNA (compared to control siRNA) in 
-PR media (~10-fold (p = 0.0027) relative to ~27-fold 
(p = 0.0009)). Collectively, these results implicate the 
involvement of these factors in the functional responses 
of NCOA4 in ovarian cancer cells.
Overexpression of NCOA4β reduces colony 
forming potential 
Since NCOA4α appears to regulate cellular 
viability in our gynecological cells (see Figure 3D and 
3E), we next investigated whether NCOA4β could elicit 
antagonistic function similar to that reported in breast and 
prostate cancers [17, 18]. We thus generated NCOA4β 
overexpressing T80, HEY, and PE-A-OCV cell lines. 
There were only slight changes in p21 protein expression 
(in T80 and HEY; Figure 5A), and no changes in short-
term viability with the exception of PE-A-OC cells which 
elicited a ~40% reduction in growth (p = 0.0129) (Figure 
5B). However, we did note a marked reduction in colony 
forming ability (Figure 5C). NCOA4β was primarily 
cytoplasmic in localization (Figure 5D) similar to prostate 
specimens [17, 31]. NCOA4β overexpression did not alter 
cellular response of HEY cells to charcoal-dextran treated 
FBS containing media (-PR [41]) and iron overload 
conditions (250 µM FAC [33, 42]) (Figure 5E). However, 
we did observe that p21 protein was increased in –PR 
media (independently of NCOA4β overexpression) 
and in FAC-treated NCOA4β overexpressing cells 
(Figure 5F). FAC treatment increased FTH1 protein 
(as expected) and was independent of NCOA4β 
overexpression. In contrast, LC3B-II was increased 
in response to -PR conditions and in response to FAC 
but was reduced with NCOA4β overexpression in –PR 
conditions (Figure 5F). We additionally observed that 
NCOA4α protein was reduced and NCOA4β protein 
was increased -PR relative to +PR replete media 
(Figure 5F). Specifically, in control cells relative to 
+PR, -PR media resulted in a reduction in NCOA4α 
(~27%, p = 0.0600) and an increase in NCOA4β mRNA 
(~1.3-fold, p = 0.0191) levels (Figure 5G). Further, in 
NCOA4β overexpressing cells relative to +PR, –PR 
conditions resulted in a reduction in NCOA4α (~48%, 
p = 0.0145) and an increase in NCOA4β mRNA (~5-fold, 
p < 0.0001) levels. We noted that these mRNA changes 
were consistent at the protein level (see Figure 5F). These 
results suggest that NCOA4β is negatively regulated by 
the presence of factors present in serum. 
NCOA4 protein expression is increased in 
malignant ovarian cancer cell lines and in 
subtypes of human OVCA 
To the best of our knowledge, there is limited 
information on the expression of NCOA4 in clinical 
specimens; one report describes an increase in NCOA4 
mRNA in invasive ovarian carcinomas (compared to 
non-malignant controls) via in situ hybridization [19]. 
We therefore assessed the expression of NCOA4 splice 
variants in patient-derived cell lines and ovarian cancer 
tissue specimens. With regard to cell lines, we assessed 
non-malignant (T80, FT194, and PE-A-OCV) and 
malignant (HEY, TOV21G, and TOV112D) gynecological 
cell types in which we identified increased NCOA4α 
(~2.5-fold, p = 0.0173) and NCOA4β (~2.5-fold, p = 
0.06) mRNA in malignant compared to non-malignant cell 
lines (Figure 6A). We also identified increased NCOA4α 
protein in malignant gynecological cells (~2.5- and ~2.9-
fold in HEY (relative to T80 and FT194, respectively, as 
precursors, and ~1.9-fold in TOV112D (relative to PE-
A-OCV as precursor)) (Figure 6B). As shown in Figure 
6C, immunohistochemical staining for NCOA4 revealed 
that it was significantly increased in a subset of ovarian 
tumors relative to normal adjacent tissues: 1) serous 
adenocarcinoma (total, moderate, and weak positive), 
2) serous papillary (moderate and weak positive), and 
3) mucinous (weak positive). Overall, these data show 
that NCOA4 mRNA (NCOA4α and NCOA4β) as well 
as protein (NCOA4α) expression is increased in ovarian 
cancers relative to controls.
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Figure 4: Cellular responses to NCOA4 knockdown is altered in response to factors present in FBS. (A) HEY cells were 
treated with control or NCOA4 siRNA in the absence (-PR) or presence (+PR) of serum factor-replete media. Cell lysates were analyzed 
by western blotting using the indicated antibodies. Data shown is representative of three independent experiments. (B) Cellular viability 
(assessed via ATP levels) of HEY cells was assessed following knockdown of NCOA4 (via siRNA) and treatment for 24 hours with +PR 
or -PR media. Three independent experiments were performed. (C) RNA was isolated from HEY cells treated with NCOA4 siRNA in +PR 
or -PR media for 24 hours and utilized for real-time PCR to assess transcript levels for total NCOA4, CD71, TWIST, and SQSTM1. Three 
independent experiments were performed. (D) Cytoplasmic and nuclear fractions from HEY cells treated for 24 hours with +PR or −PR 
media were analyzed by western blotting with the indicated antibodies. Data shown is representative of three independent experiments.
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NCOA4 protein is regulated via a proteasome- 
and autophagy-independent mechanism
NCOA4 has been shown to be regulated in an iron-
dependent manner by the E3 ubiquitin ligase HERC2 
when intracellular iron levels increase [43]. To assess 
NCOA4 protein regulation, we treated our gynecological 
cells (T80, HEY, TOV21G, T-HESC, and PE-A-OCV) for 
18 hours with MG132 (a proteasome inhibitor, at 5 µM) or 
cycloheximide (CHX, a translational inhibitor, at 2 mg/ml) 
in the absence or presence of FAC (250 µM). We observed 
that NCOA4 protein was reduced upon MG132 treatment 
in all cell lines, independent of FAC treatment suggesting 
that NCOA4 is regulated in a proteasome-independent 
manner (Figure 7A). Furthermore, NCOA4 expression 
was reduced upon CHX treatment in all cell lines 
assessed, independent of FAC treatment suggesting that 
translation is an important contributor to NCOA4 protein 
levels (Figure 7A). Since we also observed an increase 
in LC3B-II upon MG132 treatment (implicating increased 
autophagic flux [44]), we next investigated whether 
NCOA4 was degraded via the autophagic pathway. As 
shown in Figure 7B, LC3B knockdown in MG132 treated 
cells did not rescue NCOA4 protein expression suggesting 
an alternative mechanism of NCOA4 regulation. 
DISCUSSION
In vitro studies for the investigation of the transition 
from endometriosis to clear cell and/or endometrioid 
ovarian cancers has been challenging due to the limitation 
and availability of long-term cultures of endometriotic 
cells. Herein, we have successfully generated transformed 
endometriotic cells via overexpression of HRASV12A, 
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Figure 5: NCOA4β overexpression in T80, HEY, and PE-A-OCV cells reduces colony forming ability. Control and 
NCOA4β overexpressing T80, HEY, and the first batch of PE-A-OCV cells were utilized to: (A) analyze protein lysates by western blotting 
with the indicated antibodies. Three independent replicates are shown; (B) analyze cytoplasmic and nuclear fractions by western blotting 
with the indicated antibodies. Data shown is representative of three independent experiments; (C) assess cellular viability (measured 
by ATP levels). Three independent experiments were performed; and (D) to assess colony formation ability after 14 days in culture. 
Representative images (from three independent experiments) are shown. Using control and NCOA4β overexpressing HEY cells: (E) 
cellular viability (measured via ATP levels) was assessed following a 3 day exposure to –PR media or 250 µM FAC. Three independent 
experiments were performed; (F) cell lysates (in cells treated with serum factor-depleted (-PR) media for 24 hours or 250 µM FAC for 18 
hours) were analyzed by western blotting with the indicated antibodies. Data shown is representative of three independent experiments; 
and (G) Transcript levels for NCOA4α and NCOA4β were assessed via real-time PCR (cells exposed to -PR media for 24 hours or 250 µM 
FAC for 18 hours). Three independent experiments were performed.
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Figure 6: Increased NCOA4 expression in malignant gynecological cells and human OVCA tissues. (A) RNA isolated 
from T80, FT194, and PE-A-OCV (non-malignant) and HEY, TOV21G, and TOV112D (malignant) cells were used to assess transcript 
levels for NCOA4α and NCOA4β via real-time PCR. Three independent experiments were performed. (B) Cell lysates from these non-
malignant and malignant cell lines were analyzed by western blotting using the indicated antibodies. Densitometric analyses is shown in 
the right panel. Data shown is representative of three independent experiments. (C) Protein expression of NCOA4 was assessed in a human 
ovarian cancer TMA. Positive analyses was completed using the scanned image in ImageScope. Representative images of individual cores 
were captured at 6× magnification (left panel) and positive core analyses is presented in the right panel. 
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c-MYCT58A, along with p53 inactivation. These alterations 
represent those that occur early in the development 
of ovarian cancers. Specifically, in clear cell ovarian 
cancers, RAS mutations [45] and c-MYC amplifications 
[46] are prominent in addition to PIK3CA and PTEN 
alterations [47] which is expected to lead to increased 
tumorigenic potential associated with “iron addiction” 
[48]. Mutations in p53 are not commonly observed (only 
~10%) in ovarian clear cell carcinomas (OCCC) [49, 
50], although one conflicting report suggests this is a 
common mutation in all OVCA subtypes [51]. Indeed, 
iron is a potent carcinogen that increases ROS causing 
cellular damage [5]. Endometriomas are characterized 
by elevated heme and iron content [6] which is thought 
to contribute to the transition to specific subtypes of 
ovarian cancers. Regulation of intracellular iron levels is 
mediated via various means including receptors (CD71 
and FPN) that allow its import and export as well as 
storage molecules (ferritin) [12]. NCOA4 (represented 
by two well studied isoforms) is not only a recently 
identified molecule mediating regulation of intracellular 
iron content in a ferritinophagic pathway [28, 29] but 
also as a player in modulating hormone functions as a 
nuclear co-activator [15, 16, 32]. Other reported functions 
for NCOA4 include (a) regulation of DNA replication 
to modulate DNA stability [52], (b) modulation of DNA 
damage response and cellular senescence [53], and (c) 
increasing cellular proliferation and migration/invasion 
of breast as well as prostate cancer cells [17, 18]. Herein 
(as shown in Figure 7C), we have defined that NCOA4 
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is elevated in transformed endometriotic cells (relative to 
non-transformed cells), in malignant ovarian cancer cells 
and in a subset of ovarian tumors. Moreover, we have 
demonstrated that NCOA4 isoforms have the capacity to 
alter gynecological cell survival. 
Transcriptional regulation of NCOA4 mediated 
by oncogenes has not been previously reported. 
Transformation of immortalized fallopian tube fimbriae 
with SV40 LTAg and c-MYC increases CD71 and 
decreases FPN protein [27]. Further, HRAS, c-MYC, and 
E1A are reported to regulate ferritin levels which leads 
to increased intracellular labile iron and proliferative 
indices [12, 24–26, 54]. We propose that the combination 
of HRAS, c-MYC, and p53 inactivation contributes to 
NCOA4 mRNA transcription. Further work is needed to 
identify potential c-MYC binding sites in the promoter 
region of NCOA4 as well as determining whether 
inhibition of the MAPK pathway could antagonize 
NCOA4 transcription or whether p53 inhibits NCOA4 
expression. Although we identified that reduction of 
NCOA4 levels led to reduced cellular survival, we did not 
measure intracellular labile iron pool in our transformed 
endometriotic cells which would clarify whether it support 
cellular survival in an iron- and/or hormone-dependent 
manner. In this regard, our subcellular localization data 
placing NCOA4 in the cytoplasmic compartment for both 
isoforms implicates its role in both functions. This is in 
contrast to the NCOA4 localization in prostate cancer 
specimens in which the NCOA4α isoform is localized to 
the cytoplasmic compartment and the NCOA4β isoform is 
localized in the nuclear compartment [31]. 
From TCGA analyses, the DNA copy number 
of NCOA4 is not markedly altered compared to CD71 
which is notably amplified (>25%). We propose that 
NCOA4 is instead dysregulated at the protein level as 
a result of altered HERC2 E3 ubiquitin ligase activity; 
indeed, HERC2 is mutated up to 20% in various cancers 
(obtained from cBioportal [55, 56]). While NCOA4 is 
Figure 7: NCOA4 protein is regulated in a proteasome- and autophagy-independent manner. (A) Cell lysates from 
untreated T80, HEY, TOV21G, T-HESC, and PE-A-OCV or cells treated for 18 hours with 5 µM MG132, 2 μg/ml CHX, 250 µM FAC 
or a combination of MG132 with FAC or CHX with FAC were analyzed by western blotting with the indicated antibodies. Data shown 
is representative across three independent experiments. (B) Cell lysates from non-targeting control or LC3B siRNA transfected HEY 
cells treated in the absence or presence of 5 µM MG132 were analyzed by western blotting with the indicated antibodies. Data shown 
is representative across three independent experiments. (C) Schematic summarizing the results presented herein. mRNA expression of 
NCOA4α and NCOA4β are increased in transformed endometriotic cells (compared to non-transformed controls) and malignant OVCA 
cell lines (compared to non-malignant gynecological cell lines). NCOA4α protein is increased in malignant OVCA cell lines (compared to 
non-malignant gynecological cell lines). In addition, total NCOA4 protein was increased in a subset of human OVCA tumors (compared to 
normal adjacent tissues). Modulation of NCOA4 expression in T80, HEY, and PE-A-OCV cells led to changes in cellular survival.
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known to be ubiquitinated by HERC2 (for proteasome 
degradation) in an iron-dependent manner [43], we found 
that proteasome inhibition with FAC treatment did not 
prevent NCOA4 protein degradation in our gynecological 
cells. Furthermore, NCOA4 protein remained reduced 
upon proteasome inhibition with autophagy inhibition 
(via siRNA-mediated knockdown of LC3B), suggesting 
that NCOA4 is regulated in a proteasome- and autophagy-
independent manner in our gynecological cells. Our 
preliminary investigation to identify HERC2 mutations 
(which may inhibit its E3 ligase function) using the 
TCGA database [55, 56], uncovered a commonly mutated 
residue (R2126) which is expected to be “probably 
damaging” (assessed by PolyPhen-2 [57]) to the protein 
structure. Further investigations are needed to elucidate 
the mechanisms underlying NCOA4 protein dysregulation 
in ovarian cancer.
Since we identified a marked further increase in 
NCOA4β mRNA in NCOA4β overexpressing cells when 
maintained in –PR media (relative to +PR media), we 
propose that one or more factors contained within FBS 
may regulate NCOA4 expression; these factors may 
include lipophilic proteins including hormones, growth 
factors, and cytokines [58]. Indeed, NCOA4 is involved in 
regulating hormone responses (via its action as a nuclear 
receptor coactivator for androgen and estrogen receptors 
[16, 17, 32]) in addition to its novel role as a mediator of 
intracellular iron levels (as a ferritinophagic mediator [28, 
29]); we propose that NCOA4 may be involved in OVCA 
biology by both mechanisms of action. Prior data identifies 
links between estrogen/androgen levels (hormones) and 
iron signaling; for example, there is an inverse relationship 
between estrogen and body iron levels in post-menopausal 
women [59]. Furthermore, estrogen is well-established to 
regulate FPN by binding to estrogen response elements 
(ERE) within its promoter region [60]. Estrogen is an 
important contributor to ovarian cancer development 
[61] and can itself modulate p53 expression [62] which 
transcriptionally regulates ISCU expression leading to 
changes in ferritin and CD71 levels [63]. However, further 
investigations are needed to fully elucidate the roles of 
NCOA4α and NCOA4β in OVCA biology as well as their 
response to –PR media conditions. 
Our findings support a need for further investigations 
on regulatory mechanisms underlying NCOA4 isoform 
expression and function in specific subtypes of ovarian 
cancers. To this end, developing a combination NCOA4 
knockout mice [29] with an OVCA mouse model [64] may 
provide insight into the role of NCOA4 in OVCA biology. 
MATERIALS AND METHODS
Ethics and human OVCA tissue microarray
We obtained a TMA (US Biomax, Inc. 
(#BC11115b, Derwood, MD)) containing a total of 
100 core samples including 5 clear cell carcinomas, 
48 serous papillary adenocarcinomas, 14 serous 
adenocarcinomas, 12 mucinous adenocarcinomas, 1 
endometrioid adenocarcinoma, 10 lymph node metastasis 
adenocarcinoma, and 10 adjacent normal tissues which 
were de-identified and cannot be linked to the human 
subjects. The studies that were performed using this array 
as reported in this manuscript received an assessment 
of Not Human Subjects Research Determination (IRB#: 
Pro00029616) from the University of South Florida IRB 
Review Board whose Chairperson is Dr. Jorgensen. The 
TMA was stained using previously published methods 
[65] with a 1:100 dilution of the NCOA4 antibody 
(Novus Biologicals, #H00008031-M05) for a 45 minute 
incubation with an epitope retrieval solution 2 for 20 
minutes. The stained TMA was scanned using the Aperio 
ScanScope XT (Aperio Vista, CA, USA) as described 
previously [65]. Representative images were captured at 
6× magnification. Positive core analyses were determined 
using the Positive Pixel Count v.9.0 algorithm. Thresholds 
are as follows: Hue Value (Center) = 0.1; Hue Width = 0.5; 
Color Saturation Threshold = 0.04; Intensity Threshold 
Weak (Upper Limit) = 220; Intensity Threshold Weak 
(Lower Limit) = 175; Intensity Threshold Medium (Upper 
Limit) = 175; Intensity Threshold Medium (Lower Limit) 
= 100; Intensity Threshold Strong (Upper Limit) = 100; 
Intensity Threshold Strong (Lower Limit) = 0. Statistical 
Analysis (student’s nonparametric t-test) was completed in 
GraphPad Prism, and error bars represent the mean ± SD 
*p < 0.05, **p < 0.01. 
Cell culture 
Human normal immortalized (with LTAg and 
hTERT) ovarian surface epithelial T80 cells and serous 
ovarian epithelial HEY carcinoma cells were kindly 
provided by Dr. Gordon Mills (MD Anderson Cancer 
Center, Houston, TX, USA) and were maintained in RPMI 
1640 supplemented with 8% FBS and 1% penicillin/
streptomycin as previously described [33]. Human 
immortalized (with hTERT) endometrial stromal T-HESC 
cells were obtained from ATCC (Manassas, VA, USA) 
and were maintained in phenol-red free DMEM/F12 (1:1) 
supplemented with 8% charcoal-dextran treated FBS, 
500 ng/ml puromycin, 1% ITS+ Premix (#354352, BD 
Biosciences, San Jose, CA, USA), and 15 mM HEPES 
as previously described [65]. Human clear cell ovarian 
TOV21G carcinoma cells were kindly provided by Dr. 
Jonathan Lancaster (Moffitt Cancer Center, Tampa, FL, 
USA) while human endometrioid ovarian TOV112D 
carcinoma cells were obtained from ATCC (Manassas, 
VA, USA); both cell lines were maintained in MCDB 
131/Medium 199 (1:1) supplemented with 8% FBS and 
1% penicillin/streptomycin. Fallopian tube secretory 
epithelial cells (FTSEC (FT194)) were kindly provided 
by Dr. Ronald Drapkin (University of Pennsylvania, 
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Philadelphia, PA, USA) and maintained in DMEM/
F12 (1:1) supplemented with 2% Ultroser G (Crescent 
Chemical Company, #67042.1/S) and 1% penicillin/
streptomycin. T80, T-HESC, HEY, TOV21G, and 
TOV112D were authenticated by STR profiling (Genetica 
Laboratories, Cincinnati, OH, USA). The STR profiles for 
human endometriotic cells were confirmed to not match 
any profiles representing commercial cell lines deposited 
within the repository cell line database (Genetica 
Laboratories, Cincinnati, OH, USA). Furthermore, all cell 
lines were confirmed to be mycoplasma negative.
Human primary endometriotic cell isolation
Human primary endometriotic cell lines (kindly 
provided by Dr. Idhaliz Flores, Ponce, Puerto Rico) were 
obtained from four endometriotic lesions as follows: (a) 
PE-A cells, derived from a lesion in the posterior cul-
de-sac, (b) PE-B cells, derived from a lesion in the right 
mesosalpinx, (c) PE-C cells, derived from a peritoneal 
lesion, and (d) PE-D cells, derived from an endometrioma 
located on the right ovary. These cells were maintained 
in MCDB 131/Medium 199 (1:1) supplemented with 8% 
FBS and 1% penicillin/streptomycin.
Generation of human transformed endometriotic 
cells
HEK293T packaging cells were seeded at 1.5x106 
cells in 6-well plates. Following overnight adherence, 
cells were transfected with a retroviral expression plasmid 
concurrently with pCGP and pVSVG plasmids (1:1:1 
ratio) using Fugene HD (Promega, Madison, MI, USA). 
Control virus was generated using an empty pBABE-
puro expression plasmid (Addgene plasmid #1764 
[66]). Oncogenic cocktail virus was generated using 
the following at equimolar quantities (a) H-RASV12A 
(Addgene plasmid #9051, a gift from William Hahn), 
(b) c-MYCT58A (Addgene plasmid #20076, a gift from 
Juan Belmonte [67]), (c) SV40 LTAg (Addgene plasmid 
#14088, a gift from William Hahn [68]), and (d) HA-
tagged hTERT (Addgene plasmid #1772, a gift from 
Bob Weinberg [69]). Forty-eight hours after transfection, 
media supernatant (containing retrovirions) was collected, 
filtered (0.45µm), and used to infect PE-A, PE-B, PE-
C, and PE-D human primary endometriotic cells with 
8 μg/ml polybrene. Following the initial retroviral 
infection, cells were maintained for 23 days at which time 
there was no further increase in cell growth in either the 
OCV (oncogenic virus cocktail) or CV (control virus) 
infected cells. Thus, two additional rounds of retroviral 
infections were completed and cells were maintained for 
44 days, at which time both the PE-C and PE-D (CV and 
OCV infected cells) reached crisis. PE-A and PE-B control 
virus infected cells also eventually reached crisis, at which 
point the OCV infected cells, which continued to survive 
and proliferate, were considered to be transformed. We 
completed two additional rounds of infections in PE-A and 
PE-B cells (with CV and OCV retrovirions) to increase 
cell numbers available for analyses since the number of 
non-transformed cells was a limitation for the subsequent 
analyses. 
Cloning of NCOA4α and NCOA4β into a 
retroviral expression plasmid for generation of 
retroviral cell lines
RNA isolated from T80 cells using an RNeasy kit 
(QIAGEN, Germantown, MD, USA) was utilized for 
reverse transcriptase (RT)-polymerase chain reaction 
(PCR) to amplify the full-length form of NCOA4 
(NCOA4α). RNA isolated from TOV21G cells using an 
RNeasy kit (QIAGEN, Germantown, MD, USA) was 
utilized for reverse transcriptase (RT)-polymerase chain 
reaction (PCR) to amplify the shorter form of NCOA4 
(NCOA4β). The primers used are (1) 5′-GGG-GAATTC-
ACCGCC-ATG-AAT-ACC-TTC-CAA-GAC-3′ (forward 
primer) and (2) 5′-GGG-GAATTC-TCA-CAT-CTG-TAG-
AGG-AGT-TCG-3′ (reverse primer). The PCR conditions 
used were as follows: 30 min at 48°C, 2 min at 94°C 
followed by 40 cycles of 1 min at 94°C, 1 min at 55°C 
(for both NCOA4α and NCOA4β), 5 min at 68°C. The 
final extension step was set for 15 min at 72°C. Products 
were analyzed on a 1% agarose gel and the appropriately 
sized PCR products for both NCOA4α and NCOA4β 
were gel purified using the QIAquick Gel Extraction 
kit (QIAGEN, Germantown, MD, USA) following the 
manufacturer’s protocol and then cloned into the pTOPO 
vector (Invitrogen, Carlsbad, CA, USA). Positive clones 
were validated by sequencing (Moffitt Cancer Center, 
Molecular Genomics Core, Tampa, Florida, USA). 
NCOA4α and NCOA4β were then subcloned into the 
EcoRI site in the retroviral pBABE-puro (Addgene 
plasmid #1764[66]) and pQCXIN (Clontech, Mountain 
View, CA, USA) expression vectors. Large plasmid stocks 
of NCOA4α and NCOA4β in these retroviral plasmids 
were generated using the EndoFree Plasmid kit (QIAGEN, 
Germantown, MD, USA). 
HEK293T packaging cells were transfected 
with the appropriate expression vector (pBABE-puro 
or pQCXIN) or the corresponding empty vector (as 
control) as well as the pCGP and pVSVG vectors (at 
a 1:1:1 ratio). At 48 and 72 hours post-transfection, 
virus-containing supernatant was collected, filtered 
(0.45 µm), and used to infect the appropriate target 
cells with 8 μg/ml polybrene (first round of infection) or 
16 μg/ml polybrene (second round of infection). 
Cells were then expanded to T75 flasks in appropriate 
antibiotic-containing media (1 μg/ml puromycin for T80 
cells, 2 mg/ml puromycin for HEY cells, and 0.5 μg/ml 
G418 for PE-A-OCV cells).  
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Cellular treatments
Media from senescent PE-A-CV and PE-B-CV 
cells was collected (conditioned media, COM), 0.22 
mm filtered, and stored at −20°C until use in migration 
assays. Ferric ammonium citrate (FAC) was obtained from 
Fisher Scientific (Pittsburgh, PA, USA); a 50 mM stock 
was prepared in PBS and used at a final concentration of 
250 µM according to our prior work [33]. To prepare 
serum factor-depleted media (-PR), phenol-red free 
DMEM/F12 (1:1) was supplemented with 8% charcoal-
dextran treated FBS and 1% penicillin/streptomycin. 
MG132 (Fisher Scientific, Pittsburgh, PA, USA), a 
proteasome inhibitor, was prepared in dimethyl sulfoxide 
(DMSO) at 10 mM and used at a final concentration of 
5 µM while cycloheximide (CHX, Fisher Scientific, 
Pittsburgh, PA, USA), a protein synthesis inhibitor, 
was prepared in DMSO at 1 mg/ml and used at a final 
concentration of 2 μg/ml as previously described [70] in 
the presence or absence of 250 µM FAC for 18 hours.
siRNA transfection
Cells were seeded at 350,000 cells (T80, T-HESC, 
HEY, PE-A-OCV) or 1x106 cells (TOV21G) per well 
in 6-well plates and allowed to adhere overnight. Cells 
were then transfected with the appropriate siRNA using 
DharmaFECT 1 (Fisher Scientific, Pittsburgh, PA, USA) 
according to our previously published methods [71]. 
The following ON-TARGETplus siRNAs were obtained 
from GE Dharmacon (Lafayette, CO, USA): (1) non-
targeting control (D-001810-10-20), (2) NCOA4 (L-
010321-00-0005), and (3) LC3B (L-012846-00-0005). 
To obtain efficient knockdown of NCOA4, two rounds of 
siRNA transfection were performed while one round was 
completed for LC3B. 
RNA Isolation and real-time polymerase chain 
reaction (PCR)
The RNeasy Kit (QIAGEN, Valencia, CA, USA) was 
used to isolated total RNA following the manufacturer’s 
instructions. Using methods previously described [33], 
real-time PCR was performed using the One-step Master 
Mix from Applied Biosystems (#4392938, Foster City, 
CA, USA) with the following FAM-labelled probes/
primers: (1) NCOA4 (Hs00428331_g1), (2) FTH 
(Hs01694011_s1), (3) CD71 (Hs00951083_m1), (4) FPN 
(Hs00205888_m1), (5) DMT1 (Hs00167206_m1), (6) 
ISCU (Hs00384510_m1), (7) IL-6 (Hs00985639_m1), (8) 
SNAIL (Hs00195591_m1), (9) SLUG (Hs00950344_m1), 
(10) ZEB1 (Hs00232783_m1), (11) ZEB2 (Hs00207691_
m1), (12) TWIST1 (Hs00361186-m1), (13) LC3B 
(Hs00797944-s1), (14) LAMP1 (Hs00174766-m1), 
(15) SQSTM1 (Hs01061917-g1), and (16) MCOLN1 
(Hs01100653-m1). Using the Custom TaqMan® Assay 
Design Tool, FAM-labelled probes and primers specific 
for NCOA4α were designed to cross the junction between 
exon 8 and exon 9 while FAM-labelled probes and primers 
specific for NCOA4β were designed to cross the junction 
between exon 7 and exon 9. CT values were normalized to 
β-actin (#401846, Applied Biosystems, Foster City, CA, 
USA) and RNA-fold changes were calculated using the 
formula 2−ΔΔCT.
Protein isolation, SDS-PAGE, and western 
analyses
Protein lysates were prepared according to previously 
published methods [72]. Proteins were then normalized 
and loaded onto appropriate (10%) SDS-PAGE gels 
which were next transferred onto polyvinylidene fluoride 
(PVDF) membranes. As indicated in the Figure legends, 
samples were re-run to prevent overlapping detection of 
similar molecular weight antigens. Western blotting was 
conducted according to previously described methods [71]. 
Total Ras rabbit monoclonal (#3339, 1:1000), FTH rabbit 
polyclonal (#3998, 1:500), c-MYC rabbit monoclonal 
(#13987, 1:500), LC3B rabbit polyclonal (#2775, 1:1000), 
p21 mouse monoclonal (#2946, 1:250), phospho-p42/44 
MAPK rabbit polyclonal (#9101, 1:750), pAKT rabbit 
monoclonal (#4060, 1:1000), pan-AKT rabbit monoclonal 
(#4685, 1:1000), Lamin A/C mouse monoclonal (#4777, 
1:2000), PARP rabbit polyclonal (#9542, 1:1000), GAPDH 
rabbit monoclonal (#5174, 1:1000), and pan-Actin rabbit 
polyclonal (#4968, 1:500) antibodies were obtained from 
Cell Signaling Technology (Danvers, MA, USA). SV40 
Large T antigen mouse monoclonal (#554149, 1:1000) and 
p62 mouse monoclonal (#610832, 1:1000) were obtained 
from BD Biosciences (San Jose, CA, USA). NCOA4 
rabbit polyclonal (#A302–272a, 1:1000) was obtained 
from Bethyl Laboratories (Montgomery, TX, USA). CD71 
mouse monoclonal (#sc-51829, 1:250) was obtained from 
Santa Cruz Biotechnology (Dallas, TX, USA). ID1 rabbit 
antibody (1:300) was kindly provided by Dr. Miguel 
Pujana (Catalan Institute of Oncology, Barcelona, Spain). 
Densitometric analyses were completed using ImageJ 
(NIH).
Immunofluorescence
Human endometriotic cells (PE-A-CV and PE-A-
OCV as well as PE-B-CV and PE-B-OCV) were seeded 
onto glass coverslips and grown until sufficient numbers 
of cells were present prior to staining. Cells were fixed 
for 30 minutes in 4% formaldehyde and then blocked (5% 
goat serum and 0.1% Triton X-100 in PBS) for 1 hour at 
room temperature. Rabbit monoclonal antibody targeting 
γH2AX was applied at 1:400 dilution overnight at 4°C 
(#9718, Cell Signaling Technology) in a humidifying 
chamber. The following day, the cells were incubated with 
the appropriate secondary antibody (Alexa Fluor 488 goat 
anti-rabbit used at 1:500 dilution in 1% goat serum and 
0.1% Triton-X-100 in PBS) for 1 hour (in the dark). 
Oncotarget5363www.impactjournals.com/oncotarget
For staining of actin filaments, cells grown on 
coverslips were fixed and blocked as described above. 
Cells were then incubated at room temperature for 30 
minutes with 5 units of Alexa Fluor 488 Phalloidin 
(#A12379, Fisher Scientific) according to manufacturer’s 
guidelines. Slides were viewed and imaged at 63× and 20× 
magnification using a PerkinElmer UltraVIEW Confocal 
spinning disc microscope (PerkinElmer Corporation). 
Subcellular fractionation
Cytoplasmic and nuclear fractions were obtained 
using the Subcellular Protein Fractionation Kit (#78840, 
Fisher Scientific) according to manufacturer’s instructions. 
The separated fractions were then run on appropriate SDS-
PAGE gels and analyzed by western blotting. 
Cell viability assays
Cells were seeded at 2,500 cells per well in a 96-
well opaque plate. After 72 hours, the CellTiter-Glo 
Luminescent Cell Viability Assay (Promega, Madison, 
WI, USA) was performed according to manufacturer’s 
instructions. To assess changes in viability upon NCOA4 
siRNA, cells (T80, HEY, and PE-A-OCV) were re-seeded 
following the last round of transfection with siRNA. 
The following day, wells were rinsed with PBS before 
incubating the cells in serum factor-replete (+PR), serum 
factor-deplete (-PR), or FAC (250 µM) media for 24 hours. 
For control (empty vector) and NCOA4β overexpressing 
cells, cell viability was assessed following 72 hours post-
seeding. 
Migration assay
The migration assay was performed according to 
manufacturer’s protocol (#CBA-110, Cell Biolabs, San 
Diego, CA, USA). Briefly, PE-A and PE-B (infected with 
CV and OCV) cells were seeded in 300 ml serum-free 
media at 15,000 cells/well in Boyden chamber inserts 
within a 24-well plate. Complete (serum-containing) 
media (CM), as chemoattractant, was added (500 ml) to the 
bottom chamber of the well. After a 24 hour incubation, 
the upper chamber of the Boyden chamber insert was 
carefully cleaned using Q-tips and then stained for 10 
minutes with 400 ml of the provided Cell Stain Solution. 
Following extensive washing, representative light 
microscope images were captured at 100× magnification. 
Furthermore, cells were counted twice independently to 
quantify migrated cells. For treatment with senescence-
conditioned media (COM), PE-A-OCV and PE-B-OCV 
cells were seeded similarly to that described above and 
complete (CM, as control) or COM media were added as 
the chemoattractant to the bottom chamber. Following 24 
hour incubation, cells were stained and images captured 
as described above.
3D morphogenesis assay
Using published methods for sphere formation [73], 
100% Matrigel Basement Membrane Matrix (#356234, 
Fisher Scientific, Pittsburgh, PA, USA) was thawed on 
ice (in a 4°C refrigerator) overnight prior to use. The 
following day, 40 ml of the stock Matrigel was added to 
each chamber of an 8-well Chamber Slide (#PEZGS0816, 
Fisher Scientific) using pre-chilled pipet tips; this was 
then incubated at 37°C for 15 minutes to solidify. PE-A 
and PE-B (CV and OCV) cells were next seeded at 5,000 
cells in a total volume of 400 ml (containing a final 
concentration of 2% Matrigel in complete media) per 
chamber. Cells were re-fed every 4 days by removing 
the top layer of media and overlaying with fresh 
complete media containing 2% Matrigel. On the 10th day, 
representative light microscope images were captured at 
100× and 200× magnification (images were converted to 
grayscale in PowerPoint). 
Senescence assay 
Senescent cells were identified by using the 
Senescence β-Galactosidase Staining Kit (#9860, Cell 
Signaling Technology) according to manufacturer’s 
instructions. Representative images were captured using 
a light microscope at 100× magnification.
Colony formation assay
Cells were seeded at 500 cells per well in 6-well 
plates and allowed to grow for the times indicated in the 
Figure Legends. The plates were then stained with crystal 
violet and scanned. 
Statistical analyses
All analyses were performed using GraphPad 
version 6.04 Prism software (GraphPad, La Jolla, CA, 
USA) and p-values were calculated using the non-
parametric Student’s t-test. The displayed error bars 
represent the mean ± SD. NS represents non-significant 
p-values; * represents p-values ≤ 0.05; ** represents 
p-values ≤ 0.01; *** represents p-values ≤ 0.001; and 
**** represents p-values ≤ 0.0001. Where indicated, fold 
changes and percent reductions were calculated as an 
average of three independent replicates.
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